A Mycobacterium ulcerans vaccine pilot trial using an accurate low-dose challenge
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.00555-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Stephen Muhi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Mice, Inbred BALB C, Mycobacterium ulcerans, Disease Models, Animal, Buruli Ulcer. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DHAC | National Health and Medical Research Council (NHMRC).
Abstract (Originalsprache)
A Mycobacterium ulcerans human challenge model has the potential to fundamentally advance our understanding of early human immune responses to infection, while rapidly evaluating vaccines and other therapeutic interventions. Here, using a murine tail infection model, we tested a very well-characterized working cell bank of the proposed challenge isolate M. ulcerans JKD8049 in naïve and Mycobacterium bovis bacille Calmette–Guérin (BCG)-vaccinated BALB/c mice. All 10 naïve mice were successfully infected with 20 colony-forming units (CFU) of M. ulcerans [95% confidence interval (CI) 17–22 CFU] with a mean time to visible lesion of 86 days (95% CI 79–92 days). In the 10 vaccinated mice, there was a significant delay in the mean time to lesion compared to the naïve controls of 24 days ( P = 0.0003), but all mice eventually developed ulcerative lesions. This study informs a future human infection model by demonstrating the successful application of the challenge agent in this in vivo model and highlights both the promise and the problems with trying to induce protective immunity against M. ulcerans . IMPORTANCE In preparation for its proposed use in a controlled human infection model (CHIM), this study reports the successful infection of BALB/c mice using a carefully characterized, low-dose inoculum of Mycobacterium ulcerans JKD8049 (our proposed CHIM strain). We also demonstrate that Mycobacterium bovis bacille Calmette–Guérin delays the onset of disease but cannot alter the course of illness once a lesion becomes apparent. We also validate the findings of previous low-dose challenges that used less accurate methods to determine the inoculum, but our presented methodology is practical, accurate, and anticipated to be reproducible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Doherty Institute, University of Melbourne, Melbourne, Victoria, Australia.
- Victorian Infectious Diseases Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
- WHO Collaborating Centre for Mycobacterium ulcerans, Victorian Infectious Disease Reference Laboratory (VIDRL), Doherty Institute, Melbourne, Victoria, Australia.
ORCID-Profile: Stephen Muhi, Timothy P Stinear
Förderung
- DHAC | National Health and Medical Research Council (NHMRC)
Zitieren
APA
Muhi, S., Porter, J. L., & Stinear, T. P. (2024). A Mycobacterium ulcerans vaccine pilot trial using an accurate low-dose challenge. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00555-24
Vancouver
Muhi S, Porter JL, Stinear TP. A Mycobacterium ulcerans vaccine pilot trial using an accurate low-dose challenge. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00555-24
BibTeX
@article{Muhi2024,
author = {Muhi, Stephen and Porter, Jessica L and Stinear, Timothy P},
title = {A Mycobacterium ulcerans vaccine pilot trial using an accurate low-dose challenge},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.00555-24}
}
EUVIMED